Article

Wavelight executives endorse Alcon offer

Erlangen, Germany-Furthering the friendly takeover process begun in July, the WaveLight AG executive committee and supervisory board have recommended that shareholders in the refractive surgery technology company tender their shares to Alcon Inc., according to a statement released by Alcon Inc.

Erlangen, Germany-Furthering the friendly takeover process begun in July, the WaveLight AG executive committee and supervisory board have recommended that shareholders in the refractive surgery technology company tender their shares to Alcon Inc., according to a statement released by Alcon Inc.

Alcon, incorporated in Huenenberg, Switzerland, with U.S. operations based in Fort Worth, TX, had increased its offer to the equivalent of approximately $20.45 U.S. per share, a 50% premium over its initial offer. The tender offer acceptance period will conclude Sept. 11. Alcon, which currently owns on a settled basis or has contractual commitments for more than 19% of WaveLight’s shares, has expressed an intention to increase its stake to at least 75% of WaveLight’s issued shares.

The news follows the German Federal Financial Supervisory Authority approval of publication of Alcon’s tender offer document, which is available online at http://www.alcon.com/investors-media/english-confirm.asp.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
© 2025 MJH Life Sciences

All rights reserved.